The effect of rebamipide for healthy subjects with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)-induced small-intestinal injury: a prospective, randomised, double-blinded, placebo-controlled study

ISRCTN ISRCTN50390099
DOI https://doi.org/10.1186/ISRCTN50390099
Secondary identifying numbers 218044
Submission date
11/07/2007
Registration date
26/07/2007
Last edited
27/04/2011
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Digestive System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Syunji Fujimori
Scientific

2-9,Kanda Tukasa-cho Chiyoda-ku
Tokyo
101-8535
Japan

Study information

Study designDouble blind, randomised, placebo-controlled study
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typePrevention
Scientific title
Study objectivesTo evaluate the prevention by rebamipide and placebo of Non-Steroidal Anti-Inflammatory Drug (NSAID)-induced small-intestinal injury in healthy subjects.
Ethics approval(s)This trial was approved by Nippon Medical School ethical committee on the 28th March 2007.
Health condition(s) or problem(s) studiedNon-Steroidal Anti-Inflammatory Drug (NSAID)-induced small-intestinal injury
InterventionRebamipide group: rebamipide 300 mg, diclofenac 75 mg and omeprazole 20 mg every day, thrice daily (t.i.d.) for two weeks
Placebo group: placebo, diclofenac 75 mg and omeprazole 20 mg every day, t.i.d. for two weeks

The subjects will be assigned to either rebamipide group or placebo group prior to the study. All medications will be taken orally. Final evaluation was done by capsule endoscopy at two weeks.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Rebamipide
Primary outcome measureTo evaluate the preventive effect of rebamipide for NSAIDs-induced small-intestinal mucosal brakes, evaluated by capsule endoscopy at time-course of day 0 and day 14.
Secondary outcome measuresTo evaluate the preventive effect of rebamipide for NSAIDs-induced small-intestinal slight injuries, such as erythema and petechiae, evaluated by capsule endoscopy at time-course of day 0 and day 14.
Overall study start date17/07/2007
Completion date30/06/2008

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexMale
Target number of participants72
Key inclusion criteria1. Male sex
2. Aged at least 20 years
3. Body Mass Index (BMI) 18.5 - 25 kg/m^2
4. Lack of history of GastroIntestinal (GI) disorder
5. Japanese population
6. Healthy on examination by a physician
7. Subject able to comprehend and give informed consent for participation in this study
8. Signed informed consent form
Key exclusion criteria1. Active gastrointestinal disease
2. Use of ulcerogenic medications within two weeks before starting the study
3. Prior gastric or intestinal surgery
4. Pregnancy
5. Physician objection
6. Concurrent participation in any other clinical trial
Date of first enrolment17/07/2007
Date of final enrolment30/06/2008

Locations

Countries of recruitment

  • Japan

Study participating centre

2-9,Kanda Tukasa-cho Chiyoda-ku
Tokyo
101-8535
Japan

Sponsor information

Individual Sponsor (Japan)
Other

Dr Syunji Fujimori
2-9,Kanda Tukasa-cho Chiyoda-ku
Tokyo
101-8535
Japan

Funders

Funder type

Hospital/treatment centre

Nippon Medical School (Japan) - covering the incidental costs of running this trial

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/03/2011 Yes No